Literature DB >> 28371837

Characterization of the arrhythmogenic substrate in patients with arrhythmogenic right ventricular cardiomyopathy undergoing ventricular tachycardia ablation.

Senthil Kirubakaran, Caterina Bisceglia, John Silberbauer, Teresa Oloriz, Giulia Santagostino, Miki Yamase, Giuseppe Maccabelli, Nicola Trevisi, Paolo Della Bella.   

Abstract

AIMS: Arrhythmogenic right ventricular (RV) cardiomyopathy (ARVC) is associated with ventricular arrhythmias, even without RV structural disease. We aimed to characterize the RV substrate using electroanatomical mapping and to define outcomes following ventricular tachycardia (VT) ablation in patients with and without RV structural abnormalities. METHODS AND
RESULTS: Twenty-nine patients with definite or suspected ARVC undergoing VT ablation were classified as 'electrical' and 'structural' cardiomyopathy based on the absence or presence of major structural criteria. Right ventricular (RV) endocardial and epicardial mapping with assessment of bipolar and unipolar voltages, distribution of late potentials (LPs), and inducible VT morphologies were performed. The endpoints for VT ablation were VT non-inducibility and LP abolition. Fourteen patients were categorized as electrical RV cardiomyopathy and 15 were categorized as structural RV cardiomyopathy. In patients with electrical cardiomyopathy, scar was limited to the epicardial surface (epicardium 13 cm2vs. endocardium 1 cm2, P < 0.05), primarily in the outflow tract, whereas patients with structural disease had greater involvement of the endocardium. During a mean follow-up of 22 ± 11 months, the VT recurrence rate was 27%, with LP abolition being a predictor of VT-free survival (HR 0.075 (0.008-0.661), P = 0.020). There was a trend towards higher recurrence rates in structural RV cardiomyopathy (40%) compared with the electrical cardiomyopathy (15%, P = 0.17).
CONCLUSION: The development of RV structural disease in patients with ARVC is associated with extensive epicardial and endocardial scar. Conversely those patients without RV structural disease have identifiable epicardial scar limited to the RV outflow tract. Ventricular tachycardia (VT) ablation in both groups targeting LP abolition is effective in preventing VT recurrence. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2017. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Ablation; Cardiomyopathy; Ventricular tachycardia

Mesh:

Year:  2017        PMID: 28371837     DOI: 10.1093/europace/euw062

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  7 in total

Review 1.  Myocardial voltage ratio in arrhythmogenic right ventricular dysplasia/cardiomyopathy.

Authors:  Andreas Müssigbrodt; Livio Bertagnolli; Elena Efimova; Jedrzej Kosiuk; Borislav Dinov; Kerstin Bode; Simon Kircher; Nikolaos Dagres; Michael Döring; Sergio Richter; Philipp Sommer; Daniela Husser; Andreas Bollmann; Gerhard Hindricks; Arash Arya
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2017-05-23

2.  Association of regional epicardial right ventricular electrogram voltage amplitude and late gadolinium enhancement distribution on cardiac magnetic resonance in patients with arrhythmogenic right ventricular cardiomyopathy: Implications for ventricular tachycardia ablation.

Authors:  Shuanglun Xie; Benoit Desjardins; Maciej Kubala; Jackson Liang; Jiandu Yang; Rob J van der Geest; Robert Schaller; Michael Riley; David Callans; Erica Zado; Francis Marchlinski; Saman Nazarian
Journal:  Heart Rhythm       Date:  2018-03-02       Impact factor: 6.343

Review 3.  Electroanatomic voltage mapping and characterisation imaging for "right ventricle arrhythmic syndromes" beyond the arrhythmia definition: a comprehensive review.

Authors:  Franco Zoppo; Giulia Gagno; Luca Perazza; Andrea Cocciolo; Giacomo Mugnai; Diego Vaccari; Vittorio Calzolari
Journal:  Int J Cardiovasc Imaging       Date:  2021-03-24       Impact factor: 2.357

4.  Ablation strategies for arrhythmogenic right ventricular cardiomyopathy: a systematic review and meta-analysis.

Authors:  Li-Shui Shen; Li-Min Liu; Li-Hui Zheng; Feng Hu; Zhi-Cheng Hu; Shang-Yu Liu; Jin-Rui Guo; Kush Kumar Bhagat; Yan Yao
Journal:  J Geriatr Cardiol       Date:  2020-11-28       Impact factor: 3.327

Review 5.  Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) in clinical practice.

Authors:  Ka Hou Christien Li; George Bazoukis; Tong Liu; Guangping Li; William K K Wu; Sunny Hei Wong; Wing Tak Wong; Yat Sun Chan; Martin C S Wong; Katharina Wassilew; Vassilios S Vassiliou; Gary Tse
Journal:  J Arrhythm       Date:  2017-12-21

6.  Catheter ablation of ventricular tachycardia in nonischemic cardiomyopathy.

Authors:  Kenji Okubo; Lorenzo Gigli; Paolo Della Bella
Journal:  J Arrhythm       Date:  2018-08-28

7.  Ventricular tachycardia catheter ablation in arrhythmogenic right ventricular cardiomyopathy.

Authors:  Antonio Frontera; Paolo Della Bella
Journal:  HeartRhythm Case Rep       Date:  2019-12-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.